News | August 19, 2022
WuXi STA breaks ground for second manufacturing facility in US
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
WuXi STA opens a new large scale continuous manufacturing plant
Syngene's collaboration with Zoetis started in 2011
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
